New-onset and idiopathic thrombotic thrombocytopenic purpura: Incidence, diagnostic validity, and potential risk factors

American Journal of Hematology

Volumn 81, Issue 9, 2006, Pages 657-663

  Schech, Stephanie D ^a   Brinker, Allen ^b   Shatin, Deborah ^a   Burgess, Margaret ^a  

^a Center for Health Care Policy and Evaluation   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Automated data; Incidence rate; Risk factors; TTP

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DIAGNOSTIC TEST; DRUG EXPOSURE; FEMALE; HOSPITALIZATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; MALE; MEDICAL RECORD; OUTPATIENT; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; VALIDATION PROCESS;

ADULT; DIAGNOSIS, DIFFERENTIAL; HUMANS; INCIDENCE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33748125896     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20669     Document Type: Article

References (23)

1. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600.
2. George JN, Vesely SK. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Diagnosis and treatment. Cleveland Clinic J Med 2001;68(10):857-878.
3. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura: report of 25 cases and a review of the literature. Medicine 1981;60:413-428.
4. Wysowski DK, Bacsanyi J. Blood dyscrasias and hematologic reactions in ticlopidine users (letter). J Am Med Assoc 1996;276:952.
5. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. J Am Med Assoc 1999;281(9):806-810.
6. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, McCarthy LJ, Sarode R, Hatfield AJ, Feldman MD, Davidson CJ, Tsai H-M. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342:1773-1777.
7. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001;8:286-293.
8. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393-397.
9. Török TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States-Analysis of national mortality data, 1968-1991. Am J Hematol 1995;50:84-90.
10. Miller DP, Kaye JA, Shea K, Ziyadeh N, Cali C, Black C, Walker AM. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology 2004;15(2):208-215.
11. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JAK, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005;3(7):1432-1436.
12. Clark WF, Garg AX, Blake PG, Rock GA, Heidenheim P, Sackett DL. Effect of awareness of a randomized controlled trial on use of experimental therapy. J Am Med Assoc 2003;290:1351-1355.
13. Shatin D, Drinkard C, Stergachis A: United Health Group. In: Strom BL (Editor), Pharmacoepidemiology, Third ed. New York: John Wiley & Sons, 2000. p 295-305.
14. Quam L, Ellis LBM, Venus P, Clouse J, Taylor CG, Leatherman S. Using claims data for epidemiologic research: the concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population. Med Care 1993;131:498-507.
15. International Classification of Diseases, Ninth Revision, Clinical Modification, Fifth ed. Salt Lake City, UT: Medicode, Inc., 1998.
16. Physician's Current Procedural Terminology. Chicago: American Medical Association, 1998.
17. Nicol KK, Shelton BJ, Knovich MA, Owen J. Overweight individuals are at increased risk for thrombotic thrombocytopenic purpura. Am J Heme 2003;74:170-174.
18. Baron BW, Martin MS, Sucharetza BS, Jeon H, Baron JM. Four patients with both thrombotic thrombocytopenic purpura and autoimmune thrombocytopenic purpura: the concept of a mixed immune thrombocytopenia syndrome and indications for plasma exchange. J Clin Apheresis 2001;16(4):179-185.
19. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology (American Society of Hematology Education Program Book) 2004. p 407-423.
20. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. J Am Med Assoc 1999;281(9):806-810.
21. Bennett CL, Connors JM, Moake JL, Bell WR, Tarantolo SR. Clopidogrel and thrombotic thrombocytopenic purpura (letter). N Engl J Med 2000;343(16):1193- 1194.
22. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96(4):1223-1229.
23. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. J Am Med Assoc 2004;292(21):2585-2590.